This Project Grant award from the National Institute on Drug Abuse (NIDA), which falls under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc. to design, synthesize, and test non-opioid drug candidates to combat the opioid crisis. The key goals are to: 1) Design and synthesize lead compounds and characterize them chemically and pharmacologically, and 2) Characterize human induced pluripotent stem cell-derived neurons from normal individuals for response to the lead compounds, fentanyl, and other opioids. This work aims to validate a molecular target and establish a new approach for identifying leads to reverse the effects of synthetic opioids like fentanyl, which has become a major contributor to the national opioid overdose epidemic. The award period runs from March 15, 2025 to February 28, 2026.
Generated 4/1/25, 3:35 AM